Wednesday, June 19, 2013 Last update: 6:04 PM
Company Tech News as it Breaks
rEVO Biologics
News articles for rEVO Biologics:
Monday, June 10, 2013
- rEVO Biologics, an LFB Company, Announces Completion of a Dose Ranging Study of a Novel, Recombinant Form of Factor VIIa in Patients with Hemophilia A and BrEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging ... read more
Friday, February 15, 2013
- ATryn Antithrombin (Recombinant) Prevents Venous Thromboembolic Events in Pregnant Patients with Hereditary Antithrombin DeficiencyrEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant ... read more
Monday, January 28, 2013
- Hereditary Antithrombin Deficiency and rEVO Biologics’ ATryn Appears on TV Segment on Lifetime Morning Show, The Balancing Act™rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company’s lead product ATryn Antithrombin (Recombinant), in the ... read more
Thursday, January 24, 2013
- Hereditary antithrombin deficiency and rEVO Biologics’ ATryn to appear on January 28th TV segment on Lifetime morning show, The Balancing Act™rEVO Biologics announced today that hereditary antithrombin (AT) deficiency, and the use of the company’s lead product ATryn antithrombin (Recombinant), will be ... read more
Thursday, January 3, 2013
- GTC Biotherapeutics, Inc., an LFB Group Company, Announces Name Change to rEVO Biologics and Renewed Commitment to Evolving Recombinant MedicineFRAMINGHAM, Mass., Jan. 3, 2013 /PRNewswire/ -- GTC Biotherapeutics announced today that it has changed its name to rEVO Biologics. The name change reflects the recent commercial growth of the company, and better aligns with the company's business strategy of evolving recombinant medicine for the treatment of ... read more